VetStem was recently featured in a documentary about Regenerative Veterinary Medicine called Animal Pharm: Where Beasts Meet Biotech.  We’ll share more about this soon, but one interesting aspect of the film is the commentary on how advances made in veterinary medicine are translating into the human medical field.

It’s not an uncommon narrative: a new medical technology or drug emerges in the veterinary field and after research and outcome data are compiled, scientists and doctors begin to wonder how humans may benefit from the same technology.  Known as translational medicine, Animal Pharm takes a look at how we’ve begun to apply what we know about stem cell therapy for animals to human medicine.

As a leader in the field of Regenerative Veterinary Medicine, VetStem strives to remain one step ahead and we recently announced the launch of our human stem cell company, Personalized Stem Cells, Inc. (PSC).  PSC was launched to advance and legitimize human regenerative medicine, which until recently, has been largely unregulated.  Recent regulatory action by the FDA, FTC, and the Federation of State Medical Boards has made it clear however that the only allowed use of stem cells will be through legitimate FDA clinical trials.

As such, PSC plans to launch FDA approved human stem cell clinical trials later this year.  The company recently announced their first Investigational New Drug application to the FDA for the treatment of osteoarthritis in the knee.  If you are interested in more information, you can contact PSC here.

These are exciting times we’re living in.  Though our primary goal has been to improve the lives of animals, it was always in the back of our minds that the technology we’ve worked so hard to develop and advance might one day be able to help humans also.  We are excited to see this dream becoming a reality.